Intermittent vemurafenib therapy in malignant melanoma

J Dtsch Dermatol Ges. 2017 Apr;15(4):451-454. doi: 10.1111/ddg.13034. Epub 2017 Mar 15.

Authors

Nicolai Treiber¹, Margit Anna Huber¹, Lars Alexander Schneider¹, Karin Scharffetter-Kochanek¹, Erwin Schultz², Dirk Debus²

Affiliations

¹ Department of Dermatology and Allergology, University of Ulm, Ulm, Germany.
² Department of Dermatology, University Hospital of the Paracelsus Medical Private University, Nuremberg, Germany.

PMID: 28294514
DOI: 10.1111/ddg.13034

No abstract available

Publication types

Letter

MeSH terms

Antineoplastic Agents / administration & dosage
Humans
Melanoma* / drug therapy
Skin Neoplasms* / drug therapy
Vemurafenib* / administration & dosage

Substances

Antineoplastic Agents
Vemurafenib